Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Takeda’s China IP head: What pharma is still getting wrong
Asia
China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.   27 May 2026
Boehringer Ingelheim adds ex-Teva executive to patent team
Careers
A senior pharmaceutical lawyer, with experience across private practice and Big Pharma, joins the company after a decade-long tenure at Teva.   27 May 2026
AI, anxiety, and antibodies: The issues dominating life sciences
Americas
Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions.   26 May 2026
Careers
In the first of a series of interviews with women UPC judges, Ingeborg Simonsson talks to Sarah Speight about her career highs and lows, including defying expectations of women in the profession and why having a clear goal is key.   26 May 2026
Americas
Ahead of WIPR Trade Secrets West, Cooley partner Heidi Keefe says that for legal teams, caution—not business pressure—should be the priority.   26 May 2026
Americas
A US appeals court has handed the generic drugmaker victory in a closely watched dispute over a treatment for a serious inherited kidney condition, dealing a setback to its branded rival.   22 May 2026
Americas
European officials have again sided with Glenmark, concluding that the 3D mark for Boehringer’s HandiHaler device is ineligible for registration.   21 May 2026
Europe
The court has imposed a financial penalty after finding it continued promoting banned devices online despite an injunction covering five European countries.   21 May 2026
Asia
Backed by the country’s wider AI ambitions, Google has signed a deal to roll out healthcare, scientific research, and safety initiatives.   20 May 2026
Americas
The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies.   20 May 2026